# A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Study · id `cardio:ct-nct01969357` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01969357](<https://clinicaltrials.gov/study/NCT01969357>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01969357

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT01969357. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT01969357, source copy `cardio:ctgov-nct01969357-2013-10-25`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01969357, source copy `cardio:ctgov-nct01969357-2013-10-25`, retrieved 2026-10-26)
- Primary completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01969357, source copy `cardio:ctgov-nct01969357-2013-10-25`, retrieved 2026-10-26)
- Completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01969357, source copy `cardio:ctgov-nct01969357-2013-10-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01969357, source copy `cardio:ctgov-nct01969357-2013-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01969357-2013-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Placebo
- Intervention (Drug): 50 mg SP2086
- Intervention (Drug): 100 mg SP2086
- Intervention (Drug): 200 mg SP2086
- Intervention (Drug): 100 mg Sitagliptin
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 231bc5c8cefc1b145cf2c2eeb9d1e15bc785c9077c52ef37b67f30e99887cfe0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
